Novel agents and strategies for overcoming EGFR TKIs resistance

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Fei-Yu, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898214/
https://www.ncbi.nlm.nih.gov/pubmed/24410791
http://dx.doi.org/10.1186/2162-3619-3-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898214/
https://www.ncbi.nlm.nih.gov/pubmed/24410791
http://dx.doi.org/10.1186/2162-3619-3-2

Ejemplares similares